Patients who were randomized to receive PALYNZIQ 20 mg subcutaneously once daily and who achieved a ≥20% reduction in blood Phe levels from pretreatment baseline had a 62% reduction in mean blood Phe levels from pretreatment baseline to randomized withdrawal period (RWP) week 8.1
See how PALYNZIQ lowered blood Phe levelsSee the efficacy data
Learn about the recommended dosing regimenSee the dosing regimen
Find access and reimbursement support for your patientsConnect with us now
Reference: 1. PALYNZIQ [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2018.